Experts are increasingly investigating retatrutide, a promising drug created by Eli Lilly, as a significant breakthrough in body management. Unlike many previous approaches, retatrutide is a twin-action receptor targeting simultaneously GLP-1 and GIP, hormones that affect appetite and blood sugar b